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 51 
 Treatment with a frontline BCR-ABL1 tyrosine kinase inhibitor (TKI; e.g., imatinib, 52 
dasatinib, nilotinib) allows patients with chronic myeloid leukemia (CML) in chronic phase (CP) 53 
to achieve a near normal life expectancy1, whereas treatment for CML in accelerated phase 54 
(AP) is more problematic. While reports describe outcomes for patients with CML-AP at initial 55 
diagnosis2,3, outcomes have been historically worse once CP disease has progressed to AP. 56 
Approximately 50% of patients with CML-AP who receive imatinib as initial treatment develop 57 
imatinib resistance4 and experience disease progression5. Second-generation TKIs are 58 
indicated for patients with CML-CP or advanced CML resistant to/intolerant of prior therapy 59 
(including imatinib)6. After initial approval of dasatinib twice a day (BID) for the treatment of 60 
patients with CML resistant to/intolerant of imatinib in all stages, this phase 3 CA180-035 study 61 
was developed to investigate once a day (QD) or twice a day (BID) dasatinib treatment in 62 
patients with CML-AP, CML in blast phase, or Ph+ acute lymphoblastic leukemia resistant 63 
to/intolerant of imatinib. 64 
Patients were randomized to receive dasatinib at either 70 mg BID (the standard dose at 65 
the time) or 140 mg QD. Comparison of major hematologic response (MaHR) between the 66 
dosage arms was the primary objective; MaHR included either a complete hematologic 67 
response (CHR) or no evidence of leukemia. Data from the 1-year and 2-year study reports 68 
(patients with 6.5 and 15 months’ median follow-up, respectively) noted that patients with CML-69 
AP in the QD or BID arms obtained similar MaHR and major cytogenetic responses4,7. Patients 70 
who did not progress, die, or withdraw consent were followed for at least 7 years from the study 71 
start. Following the primary analysis after 2 years of the study, long-term safety outcomes in 72 
patients with clinical benefit who remained on study became the primary objective. 73 
Subsequently, efficacy, as defined by MaHR, was assessed 5 years after the study start, and 74 
safety data and date/cause of death were collected out to 7 years. The majority of the patients 75 
 
 
  5 
 
who remained on study at 2 years were in the CML-AP cohort (110/128; [86%]). Long-term 76 
efficacy and safety data, beyond 2 years, had not previously been reported in these patients 77 
with CML-AP, warranting additional follow-up.   78 
As previously described, patients were diagnosed with CML-AP based on the standard 79 
definition (i.e., hematologic criteria4 or clonal evolution); patients with progression of a prior 80 
CML-AP diagnosis after achieving a hematologic response were also eligible4. Clonal evolution 81 
included additional chromosomal abnormalities besides the Ph chromosome (e.g., +8, +19, 82 
iso17q)8. After 2 years, patients who experienced specific AEs (e.g., any-grade recurring fluid 83 
retention, including pleural and/or pericardial effusion, or any-grade gastrointestinal bleed 84 
despite dose reduction by one level) were allowed to switch from BID to QD dosing, but data 85 
were analyzed based on the initial randomization arm. After 2 years, 28 of 57 patients with 86 
CML-AP switched from BID to QD dosing and 6 patients switched from QD to BID dosing 87 
(Supplementary Table 1), limiting comparisons between the dosage arms made after 2 years. 88 
 Of 611 randomized patients, 317 (52%) were diagnosed with CML-AP at baseline and 89 
form the focus of this report. Forty (13%) patients continued to receive treatment beyond 5 90 
years. The most common reasons for discontinuation were study-drug toxicity (QD: 29%; BID: 91 
36%) or disease progression (QD: 27%; BID: 23%). The median duration of dasatinib for 92 
patients with CML-AP was 15 months (QD) or 13 months (BID) at the 5-year cutoff (Table 1). At 93 
7 years, the average daily dose of dasatinib was similar for patients enrolled based on 94 
hematologic criteria, clonal evolution, or prior diagnosis of CML-AP (Table 1).  95 
The rate of MaHR by 5 years (QD: 67%; BID: 69%) was consistent with the 15-month 96 
report4, suggesting that most patients may have reached maximum response by 15 months. 97 
The median duration of response in patients with MaHR was 54 months at 5 years for the QD 98 
arm and 55 months for the BID arm (Fig. 1). Progression due to loss of hematologic response 99 
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slightly increased in both the QD and BID dosage arms from 12% and 14%, respectively, at 2 100 
years to 15% in both arms at 5 years. The best response of CHR at any time within 5 years was 101 
reached in 51% and 54% of patients in the QD and BID arms, respectively.  102 
Dose schedule did not appear to affect 5-year rates of progression-free survival (PFS) in 103 
patients with CML-AP (Table 1 and Fig. 1). Patients with clonal evolution at enrollment had a 104 
numerically higher 5-year PFS rate (42% in both arms) compared to patients diagnosed based 105 
on hematologic status (21% in both arms) or having a prior diagnosis of CML-AP (QD: 31%; 106 
BID: 24%) (Table 1). Five-year overall survival (OS) rates were numerically higher in patients 107 
who were assigned BID versus QD dosing (Fig. 1) whether diagnosis was based on 108 
hematologic status (46% vs. 33%), clonal evolution (68% vs. 53%), or prior diagnosis of AP 109 
(60% vs. 54%) (Table 1). Although 5-year OS rates were higher for the BID versus QD arm, the 110 
hazard ratio (HR; 1.37 [confidence interval: 0.99-1.90]) suggests comparable effects.  111 
After 7 years of follow-up, 83 of 157 (53%) and 67 of 160 (42%) patients had died in the 112 
QD and BID arms, respectively, 25 (15%) and 17 (11%) within 30 days of their last dasatinib 113 
dose. Only one patient died due to study drug toxicity; the patient was enrolled into the QD arm 114 
and died <2 years on study.  115 
 Data relating to the presence or absence of mutations at baseline and at the end of 116 
treatment/disease progression were available for a total of 61 (QD) and 58 (BID) patients at 5 117 
years. The treatment arms had a similar proportion of patients with no identified mutations at 118 
baseline (QD: 59% BID: 52%) and at the end of treatment (QD: 49%; BID: 50%). Over the 119 
course of 5 years, 16 patients (QD: 10; BID: 6) with no mutation at baseline had a new mutation 120 
identified. The most common acquired mutations were T315I (QD: 9; BID: 10) and F317L (QD: 121 
5; BID: 4). Conversely, of patients with an identified baseline mutation (QD: 25; BID: 28), the 122 
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mutation was no longer detected at 5 years in nine patients (QD: 4; BID: 5). The most frequently 123 
lost mutations were E255K in the BID arm (n = 5) and M351T in the QD arm (n = 4). 124 
With respect to treatment-related AEs after 5 years of follow-up (Supplementary Fig. 1), 125 
any-grade treatment-related fluid retention events occurred more frequently in the BID (53%) 126 
versus QD (40%) arm. Treatment-related pleural effusion events of any grade slightly increased 127 
in incidence between 2 years (QD: 31 [20%]; BID: 62 [39%]) and 5 years (QD: 43 [27%]; BID: 128 
71 [44%]); grade 3–5 pleural effusion occurred in 14 (9%) and 15 (9%) patients in the QD and 129 
BID arms at 5 years, respectively. While the incidence of pleural effusion was unchanged 130 
between 5 and 7 years in this study population, others have reported a continuing risk over time 131 
after years of dasatinib treatment9.  132 
At 5 years, there were four cases (two grade 3–5) of drug-related congestive heart 133 
failure/cardiac dysfunction in patients in the BID arm. Drug-related pulmonary hypertension was 134 
diagnosed by echocardiogram in three patients and indicated by x-ray in one case; it was 135 
observed in one (grade 3–5) and three (grade 1–2) patients in the QD and BID arms, 136 
respectively, within 5 years. The case in the QD arm was diagnosed on study day 944 and the 137 
cases in the BID arm were diagnosed on study days 36, 463, and 838. There were no cases of 138 
pulmonary arterial hypertension (PAH); however, right heart catheterization is required to 139 
confirm PAH, and only one procedure was performed.  140 
The frequency of hematologic and biochemical AEs were similar between the two 141 
dosage groups and were consistent with the earlier study report4. No new safety signals were 142 
identified in patients who remained on treatment after the 5-year cutoff.         143 
 Data from the CA180-035 trial represent the largest study to date, with the longest 144 
follow-up, of dasatinib-treated patients with CML-AP. After 5 years of treatment, rates of MaHR, 145 
PFS, and OS in the QD and BID dosing arms suggest comparable efficacy with either regimen. 146 
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Maintenance of MaHR suggests that some patients with CML-AP, who are responding well to 147 
second-line dasatinib therapy and are at high risk for transplant-related mortality may not need 148 
to seek a stem cell transplant. More AEs, specifically fluid-retention events (e.g., pleural 149 
effusion), occurred in patients with CML-AP in the BID versus QD arm. The reason for higher 150 
OS in the BID arm is unclear. However, because there is no significant difference in survival 151 
between these dosages, BID dosing has a more complicated safety profile, and patients with 152 
CML-AP who respond to and tolerate dasatinib treatment can maintain long-term responses, the 153 
data reinforce the current QD dose indication for treatment of patients with advanced CML. 154 
Overall, the 5-year efficacy and 7-year safety data in dasatinib-treated patients after imatinib 155 
intolerance/resistance presented here support use of dasatinib for long-term treatment of 156 
patients diagnosed with CML-AP. 157 
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Table 1 Dosages and duration of therapy at 7 years and survival outcomes at 5 years based on CML-AP diagnosis 201 
 
Hematologic status Clonal evolution Prior AP diagnosis 
All patients diagnosed 
with CML-AP 
 QD          
(n = 67) 
BID  
(n = 64) 
QD  
(n = 55) 
BID  
(n = 61) 
QD  
(n = 34) 
BID  
(n = 31) 
QD  
(n = 157) 
BID  
(n = 160) 
Average daily 
dose, mg (range) 
119 
(26–216) 
108 
(13–178) 
94 
(20–162) 
97 
(22–171) 
106 
(34–174) 
87 
(21–206) 
NR NR 
Median duration 
of therapy, 
months (range) 
8.3 
(0.0–90.1) 
9.2 
(0.5–86.1) 
21.9 
(0.5–92.9) 
20.7 
(0.4–84.6) 
16.9 
(0.12–93.2) 
20.3 
(1.6–83.8) 
15.4a 
(0.00–67.0) 
12.5a 
(0.4–66.3) 
Median duration 
of therapy 
excluding 
interruption, 
months (range) 
7.4 
(<0.1–
89.1) 
8.3 
(0.5–85.4) 
20.9 
(0.5–92.9) 
16.7 
(0.3–83.7) 
15.4 
(0.2–91.4) 
17.3 
(1.6–81.7) 
NR NR 
PFS, % (95% CI) 
 
20.7 
(11.5–31.9)   
 
 
21.3 
(10.2–35.2) 
 
 
42.1 
(27.4–56.1) 
 
 
41.5 
(25.0–57.2) 
 
31.1 
(15.8–47.8) 
24.0 
(7.1–46.1) 
30.5 
(22.6–38.5) 
30.3 
(20.9–39.6) 
OS, % (95% CI) 
 
32.8 
(21.1–44.9) 
 
45.6 
(32.3–58.0) 
52.6 
(37.9–65.3) 
67.9 
(53.5–78.7) 
54.3 
(35.9–69.4) 
60.2 
(40.4–75.2) 
45.0 
(36.8–53.2) 
57.6 
(49.5–65.7) 
AP accelerated phase, BID twice a day, CI confidence interval; CML, chronic myeloid leukemia; NR, not reported; OS, overall 202 
survival; PFS, progression-free survival; QD, once a day  203 
aDuration of therapy for entire CML-AP population calculated at 5 years  204 
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Figure legend 1 
 2 
Fig. 1 Efficacy outcomes for patients with CML-AP by dosing schedule. a Duration of 3 
MaHR for patients who achieved MaHR, b PFS, and c OS are shown for the QD (solid lines) 4 
and BID (dashed lines) dosing groups. Efficacy analyses were conducted on the intention-to-5 
treat population of patients. BID twice a day, CI confidence interval, MaHR major hematologic 6 
response, NA not available, OS overall survival, PFS progression-free survival, QD, once a day 7 
8 
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Figure 1. 1 
 2 
 3 
4 
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Supplementary Table 1. Patients switching dosing arms between 2 and 7 years and last 1 
dose received 2 
 Schedule at randomization 
 Patients on study following the 
switch amendment (n = 114) 
Patients, n (%) QD (n = 57) BID (n = 57) 
Schedule at last dose   
QD 51 (45) 28 (25) 
BID 6 (5) 29 (25) 
Last total daily dose, mg   
QD   
<80 8 (7) 16 (14) 
80 7 (6) 3 (3) 
90 0 4 (4) 
100 12 (11) 3 (3) 
140 15 (13) 2 (2) 
>140 9 (8) 0 
BID   
<80 1 (1) 5 (4) 
80 2 (2) 7 (6) 
100 0 8 (7) 
140 1 (1) 4 (4) 
>140 2 (2) 5 (4) 
  3 
 
 
  16 
 
 
Supplementary Fig. 1 Incidence of treatment-related AEs of special interest occurring in 1 
≥10% of patients with CML-AP at 5 years. Any-grade (solid) and grade 3–5 (patterned) AEs 2 
are displayed for both the QD (black) and BID (gray) dosage groups. AE adverse event, BID 3 
twice a day, GI gastrointestinal, QD once a day.  4 
 5 
  6 
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Supplementary Fig. 1  1 
 2 
aOther hemorrhage includes bleeding other than GI bleeding or central nervous system bleeding 3 
 4 
 5 
